1. Home
  2. LLYVK vs CORT Comparison

LLYVK vs CORT Comparison

Compare LLYVK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LLYVK

Liberty Media Corporation

HOLD

Current Price

$105.60

Market Cap

8.6B

Sector

Industrials

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$120.92

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LLYVK
CORT
Founded
1991
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
9.7B
IPO Year
2025
2001

Fundamental Metrics

Financial Performance
Metric
LLYVK
CORT
Price
$105.60
$120.92
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$96.50
AVG Volume (30 Days)
264.9K
1.1M
Earning Date
02-27-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.09
Revenue
$381,951,000.00
$761,407,000.00
Revenue This Year
N/A
$26.08
Revenue Next Year
$5.52
$26.98
P/E Ratio
N/A
$1,345.00
Revenue Growth
12.18
12.79
52 Week Low
$76.94
$28.66
52 Week High
$109.75
$122.21

Technical Indicators

Market Signals
Indicator
LLYVK
CORT
Relative Strength Index (RSI) 52.41 70.05
Support Level $96.46 $77.73
Resistance Level $109.36 $122.21
Average True Range (ATR) 2.35 3.53
MACD 0.03 0.20
Stochastic Oscillator 40.53 84.57

Price Performance

Historical Comparison
LLYVK
CORT

About LLYVK Liberty Media Corporation

Liberty Live Holdings Inc focuses on live entertainment investments. The company maintains a substantial ownership position in Live Nation Entertainment, the primary international promoter of concerts, events, and ticketing through platforms like Ticketmaster, alongside sponsorship and hospitality services via QuintEvents.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: